MétaCan
Menu
Back to cohort
Record W2927248301 · doi:10.18632/oncotarget.26810

Plasma RANKL levels are not associated with breast cancer risk in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers

2019· article· en· W2927248301 on OpenAlexaffabout
Tasnim Zaman, Ping Sun, Steven A. Narod, Leonardo Salmena, Joanne Kotsopoulos

Bibliographic record

VenueOncotarget · 2019
Typearticle
Languageen
FieldMedicine
TopicGenetic factors in colorectal cancer
Canadian institutionsUniversity Health NetworkPrincess Margaret Cancer CentrePublic Health OntarioWomen's College HospitalUniversity of Toronto
Fundersnot available
KeywordsRANKLBreast cancerMedicineInternal medicineOncologyHazard ratioProportional hazards modelBRCA mutationCancerEndocrinologyConfidence intervalReceptorActivator (genetics)

Abstract

fetched live from OpenAlex

// Tasnim Zaman 1, 2 , Ping Sun 2 , Steven A. Narod 2, 3 , Leonardo Salmena 1, 2, 4 and Joanne Kotsopoulos 2, 3 1 Department of Pharmacology and Toxicology, University of Toronto, ON, M5S 1A8, Canada 2 Women&rsquo;s College Research Institute, Women&rsquo;s College Hospital, Toronto, ON, M5S 1B2, Canada 3 Dalla Lana School of Public Health, University of Toronto, ON, M5T 3M7, Canada 4 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, M5G 2M9, Canada Correspondance to: Joanne Kotsopoulos, email: joanne.kotsopoulos@wchospital.ca Keywords: receptor activator of nuclear factor &kappa;B (RANKL); breast cancer; biomarker; BRCA Received: December 12, 2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accepted: January 19, 2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Published: March 29, 2019 ABSTRACT Background: Aberrant progesterone/receptor activator of nuclear factor &kappa;&beta; (RANK) signaling has been implicated in BRCA1 breast cancer development. Furthermore, lower circulating RANKL has been reported among women with a BRCA mutation compared to non-carriers; however, there have been no reports of plasma RANKL levels and subsequent breast cancer risk. We prospectively evaluated the relationship between plasma RANKL and breast cancer risk among women with a BRCA1 or BRCA2 mutation. Methods: An enzyme-linked immunosorbent assay was used to quantify plasma RANKL levels in 184 BRCA mutation carriers. Women were stratified into high vs. low RANKL based on the median levels of the cohort (5.24 pg/ml). Kaplan-Meier survival analysis was used to estimate the cumulative incidence of breast cancer by baseline plasma RANKL and cox proportional hazards models were used to estimate the adjusted hazard ratios (HRs) and 95% confidence intervals (CI) for the association between plasma RANKL and risk. Results: Over a mean follow-up of 6.3 years (0.02-19.24), 15 incident breast cancers were identified. The eight-year cumulative incidence was 10% in the low RANKL group and 12% in the high RANKL group ( P -log-rank = 0.85). There was no significant association between plasma RANKL levels and breast cancer risk (multivariate HR high vs. low = 1.06; 95%CI 0.34-3.28; P- trend = 0.86). Conclusions: These findings suggest that circulating RANKL levels are not associated with breast cancer among BRCA mutation carriers. Pending validation in a larger sample, these findings suggest that RANKL is likely not a biomarker of breast cancer risk among BRCA mutation carriers.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.839

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.010
GPT teacher head0.244
Teacher spread0.234 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2019
Admission routes2
Has abstractyes

Explore more

Same venueOncotargetSame topicGenetic factors in colorectal cancerFrench-language works237,207